

# Frederik B Thomsen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1852275/publications.pdf>

Version: 2024-02-01

30  
papers

610  
citations

759190

12  
h-index

580810

25  
g-index

30  
all docs

30  
docs citations

30  
times ranked

1029  
citing authors

#	ARTICLE	IF	CITATIONS
1	Temporal changes in cause-specific death in men with localised prostate cancer treated with radical prostatectomy: a population-based, nationwide study. <i>Journal of Surgical Oncology</i> , 2021, 124, 867-875.	1.7	1
2	Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study. <i>PLoS ONE</i> , 2020, 15, e0228447.	2.5	23
3	Comparison of venous thromboembolic complications following urological surgery between patients with or without cancer. <i>Turkish Journal of Urology</i> , 2020, 46, 277-281.	1.3	1
4	Title is missing!. , 2020, 15, e0228447.		0
5	Title is missing!. , 2020, 15, e0228447.		0
6	Title is missing!. , 2020, 15, e0228447.		0
7	Title is missing!. , 2020, 15, e0228447.		0
8	Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e814-e821.	1.9	12
9	Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study. <i>Acta Oncologica</i> , 2019, 58, 110-118.	1.8	4
10	Results of 14 years of brachytherapy for localized prostate cancer in Denmark: the Herlev cohort. <i>Scandinavian Journal of Urology</i> , 2018, 52, 164-168.	1.0	4
11	Active surveillance for localized prostate cancer: update of a prospective single-center cohort. <i>Scandinavian Journal of Urology</i> , 2018, 52, 14-19.	1.0	12
12	Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study. <i>European Urology</i> , 2017, 72, 920-928.	1.9	21
13	The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading – a matched-pair analysis. <i>BJU International</i> , 2016, 117, 883-889.	2.5	19
14	Prognostic implications of 2005 Gleason grade modification. Population-based study of biochemical recurrence following radical prostatectomy. <i>Journal of Surgical Oncology</i> , 2016, 114, 664-670.	1.7	8
15	Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center. <i>Acta Oncologica</i> , 2016, 55, 1456-1460.	1.8	10
16	Risk of malignant melanoma in men with prostate cancer: Nationwide, population-based cohort study. <i>International Journal of Cancer</i> , 2016, 138, 2154-2160.	5.1	13
17	Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study. <i>Annals of Oncology</i> , 2016, 27, 460-466.	1.2	13
18	The Movember campaign: Impact on referral patterns and diagnosis of prostate cancer. <i>Scandinavian Journal of Public Health</i> , 2016, 44, 228-232.	2.3	54

#	ARTICLE	IF	CITATIONS
19	The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy. <i>Prostate</i> , 2015, 75, 1499-1509.	2.3	11
20	Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study. <i>European Journal of Cancer</i> , 2015, 51, 1283-1292.	2.8	18
21	Active surveillance for localized prostate cancer: An analysis of patient contacts and utilization of healthcare resources. <i>Scandinavian Journal of Urology</i> , 2015, 49, 43-50.	1.0	14
22	Repeated biopsies in patients with prostate cancer on active surveillance: clinical implications of interobserver variation in histopathological assessment. <i>BJU International</i> , 2015, 115, 599-605.	2.5	11
23	Poor association between the progression criteria in active surveillance and subsequent histopathological findings following radical prostatectomy. <i>Scandinavian Journal of Urology</i> , 2015, 49, 354-359.	1.0	5
24	Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. <i>European Urology</i> , 2015, 68, 317-324.	1.9	96
25	Survival and toxicity in patients with disseminated germ cell cancer aged 40 years and older. <i>Cancer</i> , 2014, 120, 43-51.	4.1	17
26	Prostate-specific antigen doubling time as a progression criterion in an active surveillance programme for patients with localized prostate cancer. <i>BJU International</i> , 2014, 113, E98-105.	2.5	11
27	Active surveillance for clinically localized prostate cancer – A systematic review. <i>Journal of Surgical Oncology</i> , 2014, 109, 830-835.	1.7	139
28	Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. <i>Scandinavian Journal of Urology</i> , 2014, 48, 268-275.	1.0	59
29	Active surveillance can reduce overtreatment in patients with low-risk prostate cancer. <i>Danish Medical Journal</i> , 2013, 60, A4575.	0.5	32
30	Robot-assisted radical prostatectomy is a safe procedure. <i>Danish Medical Journal</i> , 2013, 60, A4696.	0.5	2